C4 Therapeutics Financials - Benzinga

C4 Therapeutics Inc

CCCCNASDAQ

Trade with Public

Trade with Public

$3.90

0.195.26%

Last update: Sep 1, 12:57 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

C4 Therapeutics Financials

C4 Therapeutics (CCCC) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.23) by 21.74 percent. This is a 51.35 percent increase over losses of $(0.37) per share from

Benzinga Newsdesk

Nasdaq Surges Over 1%; Alibaba Shares Gain After Q4 Results

US stocks mixed, Nasdaq up 200 points. Dow down 0.43%, Nasdaq up 0.79%, S&P 500 up 0.27%. Communication services up 1.6%, utilities down 1.4%. Alibaba shares up 6% after reporting mixed Q4 results. Velo3D up 47%, Wix.com down 30%, National Vision down 25%.

Avi Kapoor

Earnings Scheduled For May 12, 2026

Benzinga Insights

PRO
C4 Therapeutics Q1 EPS $(0.20) Beats $(0.27) Estimate, Sales $6.152M Beat $3.333M Estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.27) by 25.93 percent. This is a 45.95 percent increase over losses of $(0.37) per share from

Benzinga Newsdesk

Earnings Summary: C4 Therapeutics Q4

Benzinga Insights

PRO
C4 Therapeutics Q4 EPS $(0.18) Beats $(0.31) Estimate, Sales $11.016M Beat $6.460M Estimate

C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.31) by 41.37 percent. This is a 63.27 percent increase over losses of $(0.49) per share from

Benzinga Newsdesk